269 related articles for article (PubMed ID: 20206950)
1. Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone.
Antonelli A; Ferrari SM; Fallahi P; Piaggi S; Paolicchi A; Franceschini SS; Salvi M; Ferrannini E
Metabolism; 2011 Feb; 60(2):277-83. PubMed ID: 20206950
[TBL] [Abstract][Full Text] [Related]
2. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
Antonelli A; Ferrari SM; Fallahi P; Frascerra S; Santini E; Franceschini SS; Ferrannini E
J Clin Endocrinol Metab; 2009 May; 94(5):1803-9. PubMed ID: 19276231
[TBL] [Abstract][Full Text] [Related]
3. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes.
Crescioli C; Cosmi L; Borgogni E; Santarlasci V; Gelmini S; Sottili M; Sarchielli E; Mazzinghi B; Francalanci M; Pezzatini A; Perigli G; Vannelli GB; Annunziato F; Serio M
J Endocrinol; 2007 Oct; 195(1):145-55. PubMed ID: 17911406
[TBL] [Abstract][Full Text] [Related]
4. β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy.
Antonelli A; Ferrari SM; Frascerra S; Ruffilli I; Pupilli C; Bernini G; Sellari-Franceschini S; Gelmini S; Ferrannini E; Fallahi P
J Endocrinol; 2012 May; 213(2):183-91. PubMed ID: 22378921
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease.
Antonelli A; Ferrari SM; Frascerra S; Corrado A; Pupilli C; Bernini G; Benvenga S; Ferrannini E; Fallahi P
Exp Cell Res; 2011 Jul; 317(11):1527-33. PubMed ID: 21565188
[TBL] [Abstract][Full Text] [Related]
6. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
Antonelli A; Rotondi M; Ferrari SM; Fallahi P; Romagnani P; Franceschini SS; Serio M; Ferrannini E
J Clin Endocrinol Metab; 2006 Feb; 91(2):614-20. PubMed ID: 16303841
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists.
Antonelli A; Ferrari SM; Fallahi P; Frascerra S; Piaggi S; Gelmini S; Lupi C; Minuto M; Berti P; Benvenga S; Basolo F; Orlando C; Miccoli P
Endocr Relat Cancer; 2009 Dec; 16(4):1299-311. PubMed ID: 19755523
[TBL] [Abstract][Full Text] [Related]
8. Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer.
Antonelli A; Ferrari SM; Fallahi P; Piaggi S; Di Domenicantonio A; Galleri D; Santarpia L; Basolo F; Ferrannini E; Miccoli P
Cytokine; 2012 Aug; 59(2):218-22. PubMed ID: 22633083
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists.
Antonelli A; Ferrari SM; Fallahi P; Ghiri E; Crescioli C; Romagnani P; Vitti P; Serio M; Ferrannini E
Cytokine; 2010 Jun; 50(3):260-7. PubMed ID: 20299237
[TBL] [Abstract][Full Text] [Related]
10. Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy.
Ferrari SM; Ragusa F; Paparo SR; Nasini F; Nardi M; Franceschini SS; Fallahi P; Antonelli A
Autoimmun Rev; 2019 Jul; 18(7):673-678. PubMed ID: 31059842
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor-α agonists modulate CXCL9 and CXCL11 chemokines in Graves' ophthalmopathy fibroblasts and preadipocytes.
Antonelli A; Ferrari SM; Frascerra S; Ruffilli I; Gelmini S; Minuto M; Pupilli C; Miccoli P; Sellari-Franceschini S; Ferrannini E; Fallahi P
Mol Cell Endocrinol; 2012 Feb; 349(2):255-61. PubMed ID: 22101320
[TBL] [Abstract][Full Text] [Related]
12. Induction of CXCL10 secretion by interferon-γ and tumour necrosis factor-α and its inhibition by peroxisome proliferator-activated receptor-γ agonists in cultured scleroderma fibroblasts.
Antonelli A; Ferri C; Ferrari SM; Colaci M; Giuggioli D; Fallahi P
Br J Dermatol; 2010 Sep; 163(3):650-1. PubMed ID: 20456349
[No Abstract] [Full Text] [Related]
13. Peroxisome proliferator-activated receptor-gamma ligand reduced tumor necrosis factor-alpha-induced interleukin-8 production and growth in endometriotic stromal cells.
Ohama Y; Harada T; Iwabe T; Taniguchi F; Takenaka Y; Terakawa N
Fertil Steril; 2008 Feb; 89(2):311-7. PubMed ID: 17555752
[TBL] [Abstract][Full Text] [Related]
14. Constitutive nuclear factor kappaB activity is required to elicit interferon-gamma-induced expression of chemokine CXC ligand 9 (CXCL9) and CXCL10 in human tumour cell lines.
Hiroi M; Ohmori Y
Biochem J; 2003 Dec; 376(Pt 2):393-402. PubMed ID: 12946268
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor-gamma ligands 15-deoxy-delta(12,14)-prostaglandin J2 and pioglitazone inhibit hydroxyl peroxide-induced TNF-alpha and lipopolysaccharide-induced CXC chemokine expression in neonatal rat cardiac myocytes.
Liu J; Xia Q; Zhang Q; Li H; Zhang J; Li A; Xiu R
Shock; 2009 Sep; 32(3):317-24. PubMed ID: 19174742
[TBL] [Abstract][Full Text] [Related]
16. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases.
Antonelli A; Ferrari SM; Giuggioli D; Ferrannini E; Ferri C; Fallahi P
Autoimmun Rev; 2014 Mar; 13(3):272-80. PubMed ID: 24189283
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor-gamma agonists attenuate angiotensin II-induced collagen type I expression in adventitial fibroblasts.
Zhang J; Fang NY; Gao PJ; Wu LY; Han WQ; Guo SJ; Shen WL; Zhu DL
Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):72-7. PubMed ID: 18047631
[TBL] [Abstract][Full Text] [Related]
18. Effect of PPARalpha activation of macrophages on the secretion of inflammatory cytokines in cultured adipocytes.
Murakami K; Bujo H; Unoki H; Saito Y
Eur J Pharmacol; 2007 Apr; 561(1-3):206-13. PubMed ID: 17320860
[TBL] [Abstract][Full Text] [Related]
19. Systemic sclerosis fibroblasts show specific alterations of interferon-γ and tumor necrosis factor-α-induced modulation of interleukin 6 and chemokine ligand 2.
Antonelli A; Fallahi P; Ferrari SM; Giuggioli D; Colaci M; Di Domenicantonio A; Ferri C
J Rheumatol; 2012 May; 39(5):979-85. PubMed ID: 22422499
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of tumor necrosis factor-alpha-inducible inflammatory genes by interferon-gamma is associated with altered nuclear factor-kappaB transactivation and enhanced histone deacetylase activity.
Keslacy S; Tliba O; Baidouri H; Amrani Y
Mol Pharmacol; 2007 Feb; 71(2):609-18. PubMed ID: 17108260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
